Barclays’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.75M | Sell |
50,000
-96,900
| -66% | -$7.65M | ﹤0.01% | 1992 |
|
|
2025
Q4 | $11.6M | Hold |
146,900
| – | – | ﹤0.01% | 1572 |
|
|
2025
Q3 | $9.61M | Buy |
146,900
+86,300
| +142% | +$4.21M | ﹤0.01% | 1689 |
|
|
2025
Q2 | $2.39M | Hold |
60,600
| – | – | ﹤0.01% | 2706 |
|
|
2025
Q1 | $1.83M | Sell |
60,600
-89,400
| -60% | -$2.93M | ﹤0.01% | 2698 |
|
|
2024
Q4 | $5.24M | Buy |
150,000
+50,000
| +50% | +$1.87M | ﹤0.01% | 2118 |
|
|
2024
Q3 | $4.01M | Buy |
+100,000
| New | +$4.65M | ﹤0.01% | 2272 |
|
|
2024
Q2 | – | Sell |
-25,000
| Closed | -$1.08M | – | 5080 |
|
|
2024
Q1 | $1.08M | Sell |
25,000
-30,000
| -55% | -$1.43M | ﹤0.01% | 3052 |
|
|
2023
Q4 | $2.78M | Buy |
+55,000
| New | +$2.63M | ﹤0.01% | 2641 |
|
|
2021
Q1 | – | Sell |
-6,700
| Closed | -$379K | – | 4941 |
|
|
2020
Q4 | $379K | Hold |
6,700
| – | – | ﹤0.01% | 3411 |
|
|
2020
Q3 | $318K | Sell |
6,700
-3,700
| -36% | -$206K | ﹤0.01% | 3545 |
|
|
2020
Q2 | $613K | Sell |
10,400
-16,600
| -61% | -$923K | ﹤0.01% | 3174 |
|
|
2020
Q1 | $1.28M | Sell |
27,000
-89,100
| -77% | -$4.97M | ﹤0.01% | 2711 |
|
|
2019
Q4 | $7.01M | Buy |
116,100
+12,500
| +12% | +$745K | ﹤0.01% | 1686 |
|
|
2019
Q3 | $6.21M | Buy |
103,600
+79,100
| +323% | +$5.16M | ﹤0.01% | 1662 |
|
|
2019
Q2 | $1.57M | Sell |
24,500
-42,000
| -63% | -$2.97M | ﹤0.01% | 3190 |
|
|
2019
Q1 | $5.4M | Sell |
66,500
-21,800
| -25% | -$1.41M | ﹤0.01% | 1607 |
|
|
2018
Q4 | $4.77M | Sell |
88,300
-44,900
| -34% | -$2.29M | ﹤0.01% | 1637 |
|
|
2018
Q3 | $6.87M | Buy |
133,200
+39,000
| +41% | +$1.83M | ﹤0.01% | 1523 |
|
|
2018
Q2 | $3.93M | Sell |
94,200
-39,700
| -30% | -$1.76M | ﹤0.01% | 1925 |
|
|
2018
Q1 | $5.9M | Buy |
133,900
+19,900
| +17% | +$1.01M | ﹤0.01% | 1523 |
|
|
2017
Q4 | $5.73M | Sell |
114,000
-10,500
| -8% | -$576K | ﹤0.01% | 1567 |
|
|
2017
Q3 | $6.31M | Buy |
124,500
+47,800
| +62% | +$2.5M | 0.01% | 1359 |
|
|
2017
Q2 | $3.9M | Sell |
76,700
-19,700
| -20% | -$917K | ﹤0.01% | 1649 |
|
|
2017
Q1 | $3.88M | Buy |
96,400
+49,800
| +107% | +$2.24M | ﹤0.01% | 1505 |
|
|
2016
Q4 | $2.23M | Sell |
46,600
-33,300
| -42% | -$1.32M | ﹤0.01% | 2027 |
|
|
2016
Q3 | $2.93M | Buy |
79,900
+39,300
| +97% | +$1.23M | ﹤0.01% | 1685 |
|
|
2016
Q2 | $946K | Sell |
40,600
-9,400
| -19% | -$303K | ﹤0.01% | 2662 |
|
|
2016
Q1 | $2M | Sell |
50,000
-28,600
| -36% | -$1.16M | ﹤0.01% | 1922 |
|
|
2015
Q4 | $4.79M | Sell |
78,600
-7,800
| -9% | -$421K | 0.01% | 1348 |
|
|
2015
Q3 | $3.46M | Buy |
86,400
+12,400
| +17% | +$642K | ﹤0.01% | 1633 |
|
|
2015
Q2 | $4.22M | Buy |
74,000
+18,900
| +34% | +$1.2M | ﹤0.01% | 1631 |
|
|
2015
Q1 | $3.47M | Buy |
55,100
+2,900
| +6% | +$197K | ﹤0.01% | 1842 |
|
|
2014
Q4 | $3.18M | Sell |
52,200
-13,400
| -20% | -$661K | ﹤0.01% | 2104 |
|
|
2014
Q3 | $2.49M | Sell |
65,600
-122,800
| -65% | -$4.35M | ﹤0.01% | 2457 |
|
|
2014
Q2 | $6.41M | Sell |
188,400
-350,800
| -65% | -$11M | 0.01% | 1519 |
|
|
2014
Q1 | $23.2M | Buy |
539,200
+484,900
| +893% | +$23.5M | 0.03% | 609 |
|
|
2013
Q4 | $2.12M | Sell |
54,300
-252,200
| -82% | -$8.99M | ﹤0.01% | 2613 |
|
|
2013
Q3 | $11.3M | Buy |
306,500
+147,100
| +92% | +$4.39M | 0.01% | 1055 |
|
|
2013
Q2 | $4.28M | Buy |
+159,400
| New | +$3.39M | 0.01% | 1750 |
|
Other funds holding IONS
VPM
VCM
Barclays's IONS Position: Q1 2026 in Review
Barclays reduced its Ionis Pharmaceuticals (IONS) stake by 66% in Q1 2026, selling an estimated $43.6M and leaving 289,874 shares worth $21.8M. The position accounts for 0.01% of the portfolio, ranked #1059.
Barclays first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $66.7M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Barclays held 289,874 shares of Ionis Pharmaceuticals worth $21.8M as of Q1 2026.
- Barclays sold 552,997 Ionis Pharmaceuticals shares in Q1 2026, an estimated $43.6M.
- Ionis Pharmaceuticals made up 0.01% of Barclays's portfolio in Q1 2026, its #1059 holding.
- Barclays first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Ionis Pharmaceuticals position peaked at $66.7M in Q4 2025.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.